2-(3-Hydroxy-4-methoxyphenyl)ethyl 3-O-(6-deoxy-α-L-mannopyranosyl)-6-O-[(2E)-3-(4-hydroxy-3-methoxyphenyl)-2-propenoyl]-β-D-glucopyranoside/β-D-Glucopyranoside, 2-(3-hydroxy-4-methoxyphenyl)ethyl 3-O-(6-deoxy-α-L-mannopyranosyl)-6-O-[(2E)-3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propen-1-yl]-
Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
895.3±65.0 °C at 760 mmHg
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:94410-22-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
OBJECTIVES—Previous projections of mortality from mesothelioma among French men have used the age-generation method, based on the Poisson regression model. In this study an alternative method to model mortality from mesothelioma was used to predict its future trend: this method was based on the risk function that links this mortality to past exposure to asbestos, combined with population exposure data.
METHOD—Data on past French asbestos imports were used to model the overall past exposure to asbestos in men and assess two extreme scenarios (optimistic and pessimistic) for its future trends. The number of male deaths occurring between the ages of 50 and 79, from 1997-2050, was then calculated with the risk function for mesothelioma.
RESULTS—The results showed that mortality from mesothelioma among French men aged 50-79 will continue to increase, reaching a peak averaging between 1140 (optimistic scenario) and 1300 deaths (pessimistic scenario) annually around the years 2030 and 2040, respectively. No preventive measures applied now will affect this trend before then. These results are similar to those of two other predictions of mortality from mesothelioma among French men: a peak around 2030 of 800-1600 deaths annually among men aged 25-89 years, and a peak around 2020 of 1550 deaths annually among men aged 40-84.
CONCLUSIONS—Our results indicate that between 1997 and 2050, the most optimistic and pessimistic trends of future exposure will lead to the deaths from mesothelioma of between 44 480 and 57 020 men, with a corresponding loss of from 877 200 to 1 171 500 person-years of life.
mesothelioma; risk function; mortality trends; prediction; France
Future trends in mortality of French men from mesothelioma
A. Banaei, B. Auvert, M. Goldberg, A. Gueguen, D. Luce, and S. Goldberg
The Global Physical Activity Questionnaire (GPAQ) has been used to measure physical activity (PA) and sedentary time in France, but no study has assessed its psychometric properties. This study aimed to compare the reliability as well as criterion and concurrent validity of the French version of the GPAQ with the French International Physical Activity Questionnaire long form (IPAQ-LF) and use of an accelerometer in a general adult population.
We included 92 participants (students or staff) from the Medicine Campus at the University of Lorraine, Nancy (north-eastern France). The French GPAQ was completed twice, 7 days apart, to study test-retest reliability. The IPAQ-LF was used to assess concurrent validity of the GPAQ, and participants wore an accelerometer (ActiGraph GT3X+) for 7 days to study criterion validity. Reliability as well as concurrent and criterion validity of the GPAQ were tested by the intraclass correlation coefficient (ICC), Spearman correlation coefficient for quantitative variables, and Kappa and Phi coefficients for qualitative variables. Both concurrent and criterion validity of GPAQ were assessed by Bland-Altman plots.
The GPAQ showed poor to good reliability (ICC = 0.37-0.94; Kappa = 0.50-0.62) and concurrent validity (Spearman r = 0.41-0.86), but only poor criterion validity (Spearman r = −0.22-0.42). Limits of agreement for the GPAQ and accelerometer were wide, with differences between 286.5 min/week and 601.3 min/week.
The French version of the GPAQ provides limited but acceptable reliability and validity for the measurement of PA and sedentary time. It may be used for assessing PA and sedentary time in a French adult population.
Measurement, Physical activity, Psychometric analysis, Questionnaire, Reliability, Self-report, Sitting time, Validity
Reliability and validity of the French version of the global physical activity questionnaire
Fabien Riviere,a,*† Fatima Zahra Widad,a,† Elodie Speyer,a,b,c Marie-Line Erpelding,b,c Helene Escalon,d and Anne Vuillemina
To provide estimations of partial and total prevalence of 24 cancer sites in France in 2008. The estimations of partial prevalence were compared with the previous estimations for 2002.
Nationwide estimations of incidence and survival data from cancer registries were used for partial prevalence. Nationwide incidence and mortality data were used to estimate total prevalence.
At the end of 2008, in France, nearly 3 million people still alive had received a diagnosis of cancer. Of all prevalent cases, 36% were diagnosed 0 to 5 years earlier and 43% diagnosed 6 to 10 years earlier. The cancer sites with the highest prevalence were the prostate, the breast, and the colon-rectum. The changes in partial prevalence over 5 years (2002 to 2008) were considerable (+244,000 cases) and deemed to be highly related to changes in incidence.
The present estimations update the French prevalence data and highlight the burden of cancer in the population, especially in the elderly. The methods of this study had the advantage of using recent incidence and survival data, which is necessary to show sudden changes in incidence trends and changes in survival that impact prevalence.
Electronic supplementary material
The online version of this article (doi:10.1186/s12885-015-1168-2) contains supplementary material, which is available to authorized users.
Partial prevalence, Total prevalence, Cancer burden, Incidence, Survival
Total and partial cancer prevalence in the adult French population in 2008
Marc Colonna,corresponding author1,2 Nicolas Mitton,1 Nadine Bossard,3,4,5,6 Aurelien Belot,3,4,5,6,7,8 Pascale Grosclaude,9 and the French Network of Cancer Registries (FRANCIM)